Patent & Trade Mark
Attorneys
We are
Experts in Navigating IP in the Asia Pacific Region
Working with clients in
Thanks to many years of global experience, FB Rice has a network of trusted advisors in all key jurisdictions. We turn to those advisors when assisting our clients to promote their interests.

For specific information on our Asia Pacific capability, click here.
One door to South East Asia
For a seamless service for filing and prosecuting patent and trade mark applications in South East Asia, click here.
Brett Lunn

Managing Partner

Brett Lunn
"As their interests have expanded in the Asia-Pacific region, our clients have increasingly tapped in to our broad and deep understanding of the IP regimes in that region. While it has always been a priority at FB Rice to provide our clients with a service that is technically excellent, we also continue to help them to navigate the diverse jurisdictions and cultures that make up the Asia Pacific region."
"As their interests have expanded in the Asia-Pacific region, our clients have increasingly tapped in to our broad and deep understanding of the IP regimes in that region. While it has always been a priority at FB Rice to provide our clients with a service that is technically excellent, we also continue to help them to navigate the diverse jurisdictions and cultures that make up the Asia Pacific region."
New Zealand to introduce a one-year grace period
New Zealand looks set to introduce a new one-year grace period into the Patents Act 2013 after ratifying the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) on 25 October 2018.
New Zealand looks set to introduce a new one-year grace period into the Patents Act 2013 after ratifying the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) on 25 October 2018.
16 April 2018
When is it preferable to file for a composite mark?
A registered mark provides a number of benefits; the right to exclusive use of the mark for the goods and services covered, the right to sue for infringement, as a deterrent to competitors from using the same or similar mark, and as a hurdle to registration of similar marks by competitors. The question is which version of the mark should be registered to maximise these benefits? It is a strategic decision and one that is useful to discuss with your trade mark attorney to ensure the best outcomes.
A registered mark provides a number of benefits; the right to exclusive use of the mark for the goods and services covered, the right to sue for infringement, as a deterrent to competitors from using the same or similar mark, and as a hurdle to registration of similar marks by competitors. The question is which version of the mark should be registered to maximise these benefits? It is a strategic decision and one that is useful to discuss with your trade mark attorney to ensure the best outcomes.
Jane Hutchison

Special Counsel

Jane Hutchison
Jane Hutchison is a biotechnology attorney well known for her ability to develop strong, collaborative relationships with her clients. Working with a range of research institutes and corporate clients, Jane provides information relating to drafting, ownership, inventorship and other intellectual property strategies. She develops close working relationships with her clients and they rely heavily on her strategic IP advice.
Jane Hutchison is a biotechnology attorney well known for her ability to develop strong, collaborative relationships with her clients. Working with a range of research institutes and corporate clients, Jane provides information relating to drafting, ownership, inventorship and other intellectual property strategies. She develops close working relationships with her clients and they rely heavily on her strategic IP advice.
03 September 2018
New Zealand’s second-tier patent system fails to advance
The prospect of a second-tier patent system in New Zealand has failed to advance past first base, with the New Zealand Government halting the progress of the “Advancement Patent” following its first reading.
The prospect of a second-tier patent system in New Zealand has failed to advance past first base, with the New Zealand Government halting the progress of the “Advancement Patent” following its first reading.
Expect the unexpected | Patenting antibodies in Asia
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.